Is MS treatment effective long-term?

Grant number: 1032484 | Funding period: 2012 - 2014

Completed

Abstract

Multiple Sclerosis is an illness affecting more than 20,000 Australians, and causes significant disability and social disruption in most sufferers. It is an illness which progresses over decades, and this makes it difficult to accurately determine the best treatment strategies. We propose to use a registry that has followed more than 16,000 people with MS globally to examine which treatment strategies have provided the highest benefit/risk ratio in these patients, given the great variability of disease severity seen.

Related publications (24)

Scholarly works icon

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice

Tim Spelman, Claire Meyniel, Juan Ignacio Rojas, Alessandra Lugaresi, Guillermo Izquierdo, Francois Grand'Maison, Cavit Boz, Raed Alroughani, Eva Havrdova, Dana Horakova, Gerardo Iuliano, Pierre Duquette, Murat Terzi, Pierre Grammond, Raymond Hupperts, Jeannette Lechner-Scott, Celia Oreja-Guevara, Eugenio Pucci, Freek Verheul, Marcela Fiol

2017-09-01

BACKGROUND: Characteristics at clinically isolated syndrome (CIS) examination assist in identification of patient at highest risk ..

Scholarly works icon

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

Tomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Marc Girard, Alexandre Prat, Pierre Duquette, Pierre Grammond, Patrizia Sola, Raymond Hupperts, Francois Grand'Maison, Eugenio Pucci, Cavit Boz, Raed Alroughani

2017-09-01

Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response var..

Scholarly works icon

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

Bernd Merkel, Helmut Butzkueven, Anthony L Traboulsee, Eva Havrdova, Tomas Kalincik

2017-06-01

BACKGROUND: Immunotherapy initiated early after first presentation of relapsing-remitting multiple sclerosis is associated with im..

Scholarly works icon

Data quality evaluation for observational multiple sclerosis registries

Tomas Kalincik, Jens Kuhle, Eugenio Pucci, Juan Ignacio Rojas, Magda Tsolaki, Carmen-Adella Sirbu, Mark Slee, Helmut Butzkueven

2017-04-01

OBJECTIVE: Objective and reproducible evaluation of data quality is of paramount importance for studies of 'real-world' observatio..

Scholarly works icon

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Tomas Kalincik, J William L Brown, Neil Robertson, Mark Willis, Neil Scolding, Claire M Rice, Alastair Wilkins, Owen Pearson, Tjalf Ziemssen, Michael Hutchinson, Christopher McGuigan, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard

2017-04-01

BACKGROUND: Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relap..

Scholarly works icon

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

Nathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, Jeannette Lechner-Scott, Mark Slee, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Alexandre Prat, Pierre Grammond, Raymond Hupperts, Francois Grand'Maison, Patrizia Sola, Eugenio Pucci, Roberto Bergamaschi, Celia Oreja-Guevara, Vincent Van Pesch

2017-03-01

OBJECTIVE: To evaluate variability and predictability of disability trajectories in moderately advanced and advanced multiple scle..

Scholarly works icon

Contribution of different relapse phenotypes to disability in multiple sclerosis

Tamasine Stewart, Tim Spelman, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Alexandre Prat, Alessandra Lugaresi, Francois Grand'Maison, Pierre Grammond, Patrizia Sola, Vahid Shaygannejad, Raymond Hupperts, Raed Alroughani, Celia Oreja-Guevara, Eugenio Pucci, Cavit Boz, Jeannette Lechner-Scott

2017-02-01

Scholarly works icon

Defining secondary progressive multiple sclerosis

Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, Tim Spelman, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Marc Girard, Pierre Duquette, Alexandre Prat, Alessandra Lugaresi, Francois Grand'Maison, Pierre Grammond, Raymond Hupperts, Raed Alroughani, Patrizia Sola, Cavit Boz, Eugenio Pucci, Jeanette Lechner-Scott

2016-09-01

Scholarly works icon

Pregnancy protects against long-term disability accrual in relapsing-remitting MS

VG Jokubaitis, T Kalincik, J Lorscheider, T Spelman, D Horakova, P Duquette, M Girard, A Prat, G Izquierdo, P Grammond, E Pucci, F Grand'Maison, F Granella, P Sola, R Bergamaschi, G Iuliano, D Spitaleri, S Hodgkinson, J Olascoaga, F Verheul

2016-09-01

Scholarly works icon

Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis

Vilija G Jokubaitis, Tim Spelman, Tomas Kalincik, Johannes Lorscheider, Eva Havrdova, Dana Horakova, Pierre Duquette, Marc Girard, Alexandre Prat, Guillermo Izquierdo, Pierre Grammond, Vincent Van Pesch, Eugenio Pucci, Francois Grand'Maison, Raymond Hupperts, Franco Granella, Patrizia Sola, Roberto Bergamaschi, Gerardo Iuliano, Daniele Spitaleri

2016-07-01

OBJECTIVE: To identify predictors of 10-year Expanded Disability Status Scale (EDSS) change after treatment initiation in patients..

Scholarly works icon

Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS

Tim Spelman, Tomas Kalincik, Vilija Jokubaitis, Annie Zhang, Fabio Pellegrini, Heinz Wiendl, Shibeshih Belachew, Robert Hyde, Freek Verheul, Alessandra Lugaresi, Eva Havrdova, Dana Horakova, Pierre Grammond, Pierre Duquette, Alexandre Prat, Gerardo Iuliano, Murat Terzi, Guillermo Izquierdo, Raymond MM Hupperts, Cavit Boz

2016-04-01

BACKGROUND: We compared efficacy and treatment persistence in treatment-naive patients with relapsing-remitting multiple sclerosis..

Scholarly works icon

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

Matthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, Maria Trojano, Alessandra Lugaresi, Francois Grand'Maison, Eva Havrdova, Dana Horakova, Cavit Boz, Celia Oreja-Guevara, Raed Alroughani, Gerardo Iuliano, Pierre Duquette, Marc Girard, Murat Terzi, Raymond Hupperts, Pierre Grammond, Thor Petersen, Ricardo Fernandez-Bolanos, Marcela Fiol

2016-04-01

OBJECTIVE: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatmen..

Scholarly works icon

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Tim Spelman, Orla Gray, Robyn Lucas, Helmut Butzkueven

2015-12-01

This report describes a novel Stata-based application of trigonometric regression modelling to 55 years of multiple sclerosis rela..

Scholarly works icon

Defining reliable disability outcomes in multiple sclerosis

Tomas Kalincik, Gary Cutter, Tim Spelman, Vilija Jokubaitis, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Marc Girard, Pierre Duquette, Alexandre Prat, Alessandra Lugaresi, Francois Grand'Maison, Pierre Grammond, Raymond Hupperts, Celia Oreja-Guevara, Cavit Boz, Eugenio Pucci, Roberto Bergamaschi, Jeannette Lechner-Scott

2015-11-01

Prevention of irreversible disability is currently the most important goal of disease modifying therapy for multiple sclerosis. Th..

Scholarly works icon

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

Tomas Kalincik, Vilija Jokubaitis, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Pierre Grammond, Alessandra Lugaresi, Celia Oreja-Guevara, Roberto Bergamaschi, Raymond Hupperts, Francois Grand'Maison, Eugenio Pucci, Vincent Van Pesch, Cavit Boz, Gerardo Iuliano, Ricardo Fernandez-Bolanos, Shlomo Flechter, Daniele Spitaleri, Edgardo Cristiano, Freek Verheul

2015-08-01

BACKGROUND: The results of head-to-head comparisons of injectable immunomodulators (interferon β, glatiramer acetate) have been in..

Scholarly works icon

Predictors of disability worsening in clinically isolated syndrome

Vilija G Jokubaitis, Tim Spelman, Tomas Kalincik, Guillermo Izquierdo, Francois Grand'Maison, Pierre Duquette, Marc Girard, Alessandra Lugaresi, Pierre Grammond, Raymond Hupperts, Jose Cabrera-Gomez, Celia Oreja-Guevara, Cavit Boz, Giorgio Giuliani, Ricardo Fernandez-Bolanos, Gerardo Iuliano, Jeannette Lechner-Scott, Freek Verheul, Vincent van Pesch, Tatjana Petkovska-Boskova

2015-05-01

OBJECTIVE: To assess demographic, clinical, magnetic resonance imaging, and treatment exposure predictors of time to 3 or 12-month..

Scholarly works icon

Comparative efficacy of switching to natalizumab in active multiple sclerosis

Timothy Spelman, Tomas Kalincik, Annie Zhang, Fabio Pellegrini, Heinz Wiendl, Ludwig Kappos, Larisa Tsvetkova, Shibeshih Belachew, Robert Hyde, Freek Verheul, Francois Grand-Maison, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Alessandra Lugaresi, Jeannette Lechner-Scott, Celia Oreja-Guevara, Raymond Hupperts, Thor Petersen, Michael Barnett

2015-04-01

OBJECTIVE: To compare treatment efficacy and persistence in patients who switched to natalizumab versus those who switched between..

Scholarly works icon

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

Anna He, Tim Spelman, Vilija Jokubaitis, Eva Havrdova, Dana Horakova, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Marc Girard, Eugenio Pucci, Gerardo Iuliano, Raed Alroughani, Celia Oreja-Guevara, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Patrizia Sola, Daniele Spitaleri, Franco Granella

2015-04-01

IMPORTANCE: After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicia..

Scholarly works icon

Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Tomas Kalincik, Dana Horakova, Tim Spelman, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Csilla Rozsa, Pierre Grammond, Raed Alroughani, Pierre Duquette, Marc Girard, Eugenio Pucci, Jeannette Lechner-Scott, Mark Slee, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Raymond Hupperts, Freek Verheul, Suzanne Hodgkinson

2015-03-01

OBJECTIVE: In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians..

Scholarly works icon

Seasonal Variation of Relapse Rate in Multiple Sclerosis is Latitude Dependent

Tim Spelman, Orla Gray, Maria Trojano, Thor Petersen, Guillermo Izquierdo, Alessandra Lugaresi, Raymond Hupperts, Roberto Bergamaschi, Pierre Duquette, Pierre Grammond, Giorgio Giuliani, Cavit Boz, Freek Verheul, Celia Oreja-Guevara, Michael Barnett, Francois Grand'Maison, Maria Edite Rio, Jeannette Lechner-Scott, Vincent Van Pesch, Ricardo Fernandez Bolanos

2014-12-01

OBJECTIVE: Previous studies assessing seasonal variation of relapse onset in multiple sclerosis have had conflicting results. Smal..

Scholarly works icon

Risk of relapse phenotype recurrence in multiple sclerosis

Tomas Kalincik, Katherine Buzzard, Vilija Jokubaitis, Maria Trojano, Pierre Duquette, Guillermo Izquierdo, Marc Girard, Alessandra Lugaresi, Pierre Grammond, Francois Grand'Maison, Celia Oreja-Guevara, Cavit Boz, Raymond Hupperts, Thor Petersen, Giorgio Giuliani, Gerardo Iuliano, Jeannette Lechner-Scott, Michael Barnett, Roberto Bergamaschi, Vincent Van Pesch

2014-10-01

OBJECTIVES: The aim was to analyse risk of relapse phenotype recurrence in multiple sclerosis and to characterise the effect of de..

Scholarly works icon

Fingolimod after natalizumab and the risk of short-term relapse

Vilija G Jokubaitis, Vivien Li, Tomas Kalincik, Guillermo Izquierdo, Suzanne Hodgkinson, Raed Alroughani, Jeannette Lechner-Scott, Alessandra Lugaresi, Pierre Duquette, Marc Girard, Michael Barnett, Francois Grand'Maison, Maria Trojano, Mark Slee, Giorgio Giuliani, Cameron Shaw, Cavit Boz, Daniele LA Spitaleri, Freek Verheul, Jodi Haartsen

2014-04-08

OBJECTIVE: To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to tha..

Scholarly works icon

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

Tomas Kalincik, Vino Vivek, Vilija Jokubaitis, Jeannette Lechner-Scott, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Francois Grand'Maison, Raymond Hupperts, Celia Oreja-Guevara, Roberto Bergamaschi, Gerardo Iuliano, Raed Alroughani, Vincent Van Pesch, Maria Pia Amato, Mark Slee, Freek Verheul, Ricardo Fernandez-Bolanos, Marcela Fiol, Daniele La Spitaleri

2013-12-01

The aim of this work was to evaluate sex differences in the incidence of multiple sclerosis relapses; assess the relationship betw..

Scholarly works icon

Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome

Claire Meyniel, Timothy Spelman, Vilija G Jokubaitis, Maria Trojano, Guillermo Izquierdo, Francois Grand'Maison, Celia Oreja-Guevara, Cavit Boz, Alessandra Lugaresi, Marc Girard, Pierre Grammond, Gerardo Iuliano, Marcela Fiol, Jose Antonio Cabrera-Gomez, Ricardo Fernandez-Bolanos, Giorgio Giuliani, Jeannette Lechner-Scott, Edgardo Cristiano, Joseph Herbert, Tatjana Petkovska-Boskova

2012-06-29

OBJECTIVES: We conducted a prospective study, MSBASIS, to assess factors leading to first treatment discontinuation in patients wi..

University of Melbourne Researchers